SMAD4 and cancer: In conclusion, this study supports the potential of RNA analyses in the clinical classification of SMAD4 splicing variants in order to ensure tailored genetic counseling, management, and surveillance for patients with a suspected genetic predisposition to GI polyposis and/or cancer.